⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30820769 | 1.00 | — | — | |
| SCHEMBL9919116 | 0.74 | — | — | |
| SCHEMBL29737998 | 0.74 | — | — | |
| SCHEMBL30390034 | 0.74 | — | — | |
| SCHEMBL13003518 | 0.74 | — | — | |
| SCHEMBL31539802 | 0.74 | — | — | |
| SCHEMBL4123340 | 0.74 | — | — | |
| SCHEMBL1205413 | 0.74 | — | — | |
| SCHEMBL31082078 | 0.74 | — | — | |
| SCHEMBL29480787 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102898358-A | Preparation method of fluoropyridine compounds | SHANGHAI TITAN TECHNOLOGY CO LTD | 2013-01-30 | — | — | CN | claimed |
| CN-112189010-B | Triazole N-linked carbamoyl cyclohexyl acid as LPA antagonists | 百时美施贵宝公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260098029-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | Bugworks Research, Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12509442-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-12-30 | — | — | US | disclosed |
| WO-2025264818-A1 | STAT6 MODULATORS AND METHODS OF USES THEREOF | RAYTHERA, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4648763-A2 | COMPOUNDS FOR FGFRS INHIBITORS | Cogent Biosciences, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2025-10-02 | — | — | US | disclosed |
| EP-4624465-A1 | COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2025-10-01 | — | — | EP | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| EP-2118097-A1 | 1-OXA-3-AZASPIRO[4,5]DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009095377-A1 | SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | WO | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008096260-A1 | 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS | PFIZER INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008092888-A1 | 1-OXA-3-AZASPIRO[4,5]DECAN--2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092891-A1 | 1-OXA-3-AZASPIRO(4.5)DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |